InteRNA Technologies B.V.

One of the fastest moving fields in today's biomedical research concerns small non-coding RNAs in general and microRNA (miRNA) in particular. As insights into the role of these RNA species in health and disease are emerging at high speed, so are the opportunities for developing new diagnostic, prognostic and therapeutic applications.


InteRNA Technologies focuses on these developments by translating its proprietary miRNA sequences and discovery technologies into successful clinical and commercial products.

InteRNA Technologies has currently apporximately 15% of the human miRNA sequences in its patent portfolio.

News/Press releases:

08-07-2010: InteRNA Technologies announces establishment of Scientific Advisory Board more information

02-11-2009: InteRNA Technologies and Dana-Farber Cancer Institute to collaborate on the role of microRNAs in cancer pathways more information

06-07-2009: InteRNA Technologies joins TI Pharma by signing new project to develop novel anti-angiogenic miRNA-based therapeutics more information

22-04-2009: InteRNA Technologies and Radboud University Nijmegen
Medical Centre to Develop microRNA-based Therapeutics for
Prostate Cancer more information

07-11-2008: InteRNA Technologies and Cenix BioScience Ink Research Agreement for miRNA Drug Discovery more information

06-11-2008: InteRNA Technologies Joins European SIROCCO Consortium to Study RNA Silencing more information

30-10-2008: InteRNA Technologies and VU University Medical Center to Develop microRNA-based Diagnostics and Therapeutics for Cancer more information

 

Vacancies:

Project Manager R&D, more information

Technician molecular/cell biology, more information

 



InteRNA Technologies B.V.
Hugo R. Kruyt building

Padualaan 8
3584 CH Utrecht
The Netherlands
T: +31 30 253 23 86
© 2007-2010 InteRNA Technologies B.V. - Terms of Use - Contact